CERUS Q2 FY26 earnings call CERS

Cerus reported strong performance in its US Intercept Platelet and IFC franchises. The US platelet market penetration is estimated at two-thirds, with significant opportunities for continued share gains in the remaining one-third. The collaboration with Blood Centers of America (BCA) is a positive contributor, leading to increased engagement and new customers. Nationwide, IFC currently holds approximately 10% market share, highlighting a substantial growth opportunity. A major academic hospital in the Northeast recently adopted IFC 100% based on its immediate availability, five-day post-thaw shelf life, and lower cost compared to cryo-AHF and fibrinogen concentrates.

The company noted positive momentum across its EMEA business, driven by the continued rollout of the next-generation INT200 illumination device and further penetration of its core platelet franchise. A new multi-year contract was signed with the French Blood Establishment (EFS) in late April, providing greater visibility into medium-term revenue and serving as an important clinical validation. Interest in Intercept is also growing in Asia-Pacific, with current penetration below 1% across the region, presenting significant long-term growth opportunities in markets like China and Japan.

Cerus made meaningful strides in advancing its innovation portfolio. The PMA for the IEP200 for platelets was submitted to the US FDA, with potential regulatory approval as early as the first half of 2027. For Intercept Red Blood Cells (RBC), the company remains on track to announce top-line results from its Phase 3 Reddish trial during the fourth quarter of 2026. Additionally, the BARDA 2024 contract was expanded by nearly $22 million, increasing the total potential value to over $270 million, to support PMA-related activities for Intercept RBC in the US.

Cerus enhanced its financial strength through a recently completed debt refinancing. This included a $30 million reduction in the term loan balance and an expansion of the revolving credit facility's size and flexibility. The refinancing is expected to reduce annual interest expense by up to $3.5 million, further improving the company's ability to achieve its bottom-line goals and self-fund market development and product innovation in a financially disciplined manner.

The company successfully completed its Notified Body Recertification Audit with zero nonconformities, ensuring the maintenance of its CE and MD-STAT certifications. This reflects the strength of its quality management system and commitment to quality. Cerus is also transitioning its IFC sales to a kit model, with 70% of Q2 sales in kit form, and expects essentially all IFC sales to be in kit form by 2027, which is anticipated to benefit gross margins.

Vivek Jayaraman concluded his first month as CEO, expressing strong confidence in Cerus' business, team, technology, and mission. He highlighted the solid top-line growth, meaningful pipeline progress, and improving financial strength as key drivers. The company remains focused on expanding patient access to safer blood globally and creating long-term shareholder value through continued execution against its core priorities of sustainable double-digit growth, advancing innovation, and strengthening its financial foundation.